Cinnarizine is a medication derivative of piperazine, and characterized as an antihistamine and a calcium channel blocker,[1] it is also known to promote cerebral blood flow, and so is used to treat cerebral apoplexy, post-trauma cerebral symptoms, and cerebral arteriosclerosis.[2] However, it is more commonly prescribed for nausea and vomiting due to motion sickness [3] or other sources such as chemotherapy,[4] vertigo,[5] or Ménière's disease.[6] Cinnarizine was first synthesized by Janssen Pharmaceutica in 1955. The nonproprietary name is derived from the cinnamyl substituent on one of the nitrogen atoms, combined with the generic ending “-rizine” for “antihistaminics/cerebral (or peripheral) vasodilators”.[7] It is not available in the United States or Canada. It is manufactured and marketed in Bangladesh under the trade name Suzaraon by Rephco Pharmaceuticals Limited. It has also been cited as one of the most used drugs for seasickness within the British Royal Navy.[8]
Starting at
(E)-1-(Diphenylmethyl)-4-(3-phenylprop-2-enyl)piperazine |
Trade names | Stugeron, Stunarone, Arlevert, Diznil-25 |
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
US: C (Risk not ruled out) |
Legal status | UK: Pharmacy medicines |
Routes of administration |
Oral |
Biological half-life | 3–4 h |
CAS Number | 298-57-7 |
ATC code | N07CA02 |
PubChem | CID: 1547484 |
DrugBank | DB00568 |
ChemSpider | 1264793 |
UNII | 3DI2E1X18L |
KEGG | D01295 |
ChEBI | CHEBI:31403 |
ChEMBL | CHEMBL43064 |
Formula | C26H28N2 |
Molecular mass | 368.514 g/mol |
SMILES[show] |
|
InChI[show] |
Reviews
There are no reviews yet.